Navigation Links
Phosphate Binder Use Has Declined Over the Past Two Years in the U.S. Dialysis Setting, While Sensipar Use in Hemodialysis has Declined Since Last Year
Date:6/5/2013

EXTON, Pa., June 5, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the use of phosphate binders in the U.S. has declined in both the hemodialysis and peritoneal dialysis setting over the past two years.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

The ChartTrends: Bone and Mineral Metabolism in Dialysis (U.S.) 2013 report, the third ChartTrends dialysis report that has published since the dialysis bundle legislation was implemented in January 2011, finds that physicians are also initiating phosphate binders at higher serum phosphorous levels compared to last year. In addition, a significantly higher percentage of patient charts indicate that cost and the belief that phosphorous is low in the priority of treatment as two reasons for non-binder use compared to 2012.

The report also finds that Sanofi's sevelamer (Renagel, Renvela) is the market share leader in the dialysis patient population, with little change in share amongst the other binder brands compared to last year, with the exception of a decline in the use of calcium acetate.

Patients on non-calcium based binders (particularly Shire's Fosrenol) are more likely to be on Amgen's Sensipar compared to those on calcium-based binders, particularly calcium acetate.  From 2012 to 2013, use of Sensipar appears to be declining in the hemodialysis patient population.

"Despite the delay in the inclusion of orals in the dialysis bundle, we are starting to see changes in the dialysis setting likely driven by increased scrutiny and awareness of the total costs of treatment," said BioTrends Director Rob Dubman . "For example, we are now finding a rise in the use of nutritional Vitamin D and less use of AbbVie's Zemplar compared with 2012."

ChartTrends: Bone and Mineral Metabolism in Dialysis (U.S.) 2013 is a syndicated report series, in which 251 U.S. nephrologists provided patient chart data on 1,014 dialysis patients in the United States to uncover the actual management related to bone and mineral metabolism. Through an in-depth review of patient charts, details such as product dosing and titration, switching, concomitant medications and a host of laboratory and patient demographic variables, help define patient types and identify therapy triggers. The study also evaluates referral patterns, co-morbidities, concomitant medications, blood transfusions, hospitalizations and a host of other patient demographics and laboratory data.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com  


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. EU5 Nephrologists Report a Stabilization of Phosphate Binder Treatment Prevalence in the Late-Stage CKD and Dialysis Patient Populations
2. Mission Pharmacal Company Introduces Prednisolone Sodium Phosphate Oral Solution 25mg/5mL
3. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
4. Richard Wolf Medical Instruments Corporation: 40 Years of Innovation
5. CalHIPSO Enrolls Over 7,700 Providers in EHR Implementation Program, Hits Other Key Milestones After First Two Years
6. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
7. NAMS Journal Menopause Reflects on the WHI 10 Years Later
8. Particle Measuring Systems® Celebrates 40 Years of Leadership
9. Leading Pension Annuity Provider Legal & General, Celebrates 175 Years
10. Multiple Sclerosis Association of Americas MRI Institute Marks 10 Years of Helping Individuals with Multiple Sclerosis Obtain MRIs
11. Abbott, The Abbott Fund And Direct Relief International Reach Key HIV Testing Milestones: 20 Million Tests Provided Over 10 Years, And More Than 150,000 HIV Cases Prevented In Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Surgical Procedure Volumes: Global Analysis (United States, ... Australia, Canada)" report to their offering. ... an essential tool for healthcare business planners, provides surgical ... looks at surgery trends with an in-depth analysis of ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
Breaking Medicine News(10 mins):